Skip to content

Author

B. Maiorano

We have 2 of 192 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group

Immune checkpoint inhibitor (ICI)–based combinations represent the standard first-line treatment for metastatic clear cell renal cell carcinoma (mRCC), although robust biomarkers for treatment selection remain undefined. We conducted a systematic review to identify biomarkers assessed in randomized clinical trials (RCT...

A. A. Valsecchi, M. Maffezzoli, M. Cursano et al. · 0 citations
#explainable ai Sep 2026

Machine learning integrated explainable artificial intelligence in predicting toxicities of enfortumab vedotin in urothelial carcinoma: an exploratory study.

BACKGROUND Enfortumab vedotin (EV) therapy for advanced urothelial carcinoma is limited by adverse events (AEs). Early identification of high-risk patients is needed. This proof-of-concept study evaluated whether machine learning (ML) with explainable AI (SHAP) could predict EV toxicities using real-world data. RESEA...

K. Sridharan, Mattia Alberto Di Civita, G. Sivaramakrishnan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.